Atlantic Union Bankshares Corp Has $8.38 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Atlantic Union Bankshares Corp cut its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,147 shares of the company's stock after selling 777 shares during the period. Atlantic Union Bankshares Corp's holdings in Eli Lilly and Company were worth $8,380,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of LLY. WNY Asset Management LLC raised its stake in shares of Eli Lilly and Company by 3.6% during the first quarter. WNY Asset Management LLC now owns 4,962 shares of the company's stock worth $4,098,000 after buying an additional 171 shares during the last quarter. IFP Advisors Inc grew its holdings in Eli Lilly and Company by 13.0% during the first quarter. IFP Advisors Inc now owns 15,804 shares of the company's stock valued at $13,056,000 after purchasing an additional 1,813 shares during the period. Aspen Capital Management LLC acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $264,000. OneAscent Financial Services LLC grew its holdings in Eli Lilly and Company by 117.3% during the first quarter. OneAscent Financial Services LLC now owns 10,428 shares of the company's stock valued at $8,554,000 after purchasing an additional 5,630 shares during the period. Finally, Morse Asset Management Inc grew its holdings in Eli Lilly and Company by 2.6% during the first quarter. Morse Asset Management Inc now owns 11,019 shares of the company's stock valued at $9,101,000 after purchasing an additional 281 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $771.78 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a market capitalization of $731.45 billion, a P/E ratio of 62.80, a P/E/G ratio of 1.12 and a beta of 0.40. The firm has a 50-day moving average price of $767.03 and a two-hundred day moving average price of $800.02.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.58 earnings per share. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. Wall Street Zen cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday, June 28th. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Guggenheim increased their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday, July 11th. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.